GO:0010920 negative regulation of inositol phosphate biosynthetic process: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010920 describes any process that decreases the rate, frequency or extent of inositol phosphate biosynthesis, a central signaling node in eukaryotic cells.
• Inositol phosphates are water-soluble signaling molecules derived from myo-inositol; their production is tightly controlled to prevent aberrant calcium mobilization and lipid signaling [2,4].
• Negative regulation occurs at multiple levels, including transcriptional control, post-translational modification of biosynthetic enzymes, and feedback inhibition by downstream products [2,6].
• Dysregulated inositol phosphate biosynthesis is linked to cancer progression, bone disorders, and immune cell signaling defects [3,5,8].
• Key experimental approaches include CRISPR knockout of biosynthetic enzymes, phosphoinositide profiling, and live-cell calcium imaging [2,3].
• EDITGENE provides CRISPR cell models (KO, point mutation, knock-in, overexpression) and library screening to dissect this pathway in disease contexts.
Description
Inositol phosphates are a family of soluble signaling molecules generated by the stepwise phosphorylation of myo-inositol. They regulate diverse cellular processes including calcium mobilization, vesicle trafficking, and nuclear signaling. The biosynthetic routes that produce these molecules are subject to negative regulation, ensuring that signaling output is proportionate to physiological demand. GO:0010920, negative regulation of inositol phosphate biosynthetic process, captures the mechanisms that dampen this production [2,4]. Understanding this regulation is critical because excessive or mislocalized inositol phosphate signaling contributes to cancer, immune dysfunction, and developmental disorders [3,5,8]. Researchers study this process using genetic, biochemical, and imaging approaches, often leveraging CRISPR-based models to perturb key enzymes and measure downstream effects [2,3].
negative regulation of inositol phosphate biosynthetic process At A Glance
| GO ID | GO:0010920 |
|---|---|
| GO term | negative regulation of inositol phosphate biosynthetic process |
| Ontology | biological_process |
| Synonym | negative regulation of inositol phosphate biosynthesis |
| Major function | Dampening the production of inositol phosphate signaling molecules |
| Key enzymes | Inositol polyphosphate kinases (IP6K2), inositol monophosphatases (IMPAD1), and phospholipase C isoforms [3,5] |
| Regulatory inputs | Calcium signaling, receptor tyrosine kinases, and inositol pyrophosphate feedback [2,6] |
| Disease relevance | Cancer, opsismodysplasia, B-cell signaling disorders [3,5,8] |
What Is GO:0010920?
GO:0010920 is a biological process term defined as any process that decreases the rate, frequency or extent of inositol phosphate biosynthesis. Inositol phosphate biosynthetic processes are the chemical reactions and pathways resulting in the formation of an inositol phosphate, a 1,2,3,4,5,6-cyclohexanehexol with one or more phosphate groups attached. This term encompasses negative feedback loops, inhibitory post-translational modifications, and transcriptional repression of biosynthetic enzymes.
Why Is negative regulation of inositol phosphate biosynthetic process Important in Cell Biology?
Negative regulation of inositol phosphate biosynthesis is essential for preventing excessive calcium release and maintaining cellular homeostasis. In immune cells, uncontrolled inositol phosphate formation leads to aberrant B-cell activation. In cancer, dysregulated inositol phosphate signaling promotes tumor progression and therapy resistance. Moreover, mutations in inositol phosphate pathway genes cause skeletal disorders such as opsismodysplasia. Thus, understanding this negative regulation provides insights into fundamental signaling mechanisms and identifies therapeutic targets.
• Prevents calcium overload and excitotoxicity in neurons.
• Controls B-cell receptor signaling and immune tolerance.
• Modulates tumor progression in clear cell renal cell carcinoma.
• Regulates bone development; mutations cause opsismodysplasia.
• Influences plant phosphoinositide signaling and stress responses.
• Affects platelet activation and thrombosis.
• Integrates with inositol pyrophosphate signaling in land plants.
• Impacts bioavailability of dietary inositol phosphates.
• Provides feedback control on GPCR and RTK pathways.
• Serves as a target for CRISPR-based pathway dissection.
What Happens During negative regulation of inositol phosphate biosynthetic process?
Feedback inhibition by downstream inositol pyrophosphates
In simple terms: When cells make too much of certain inositol phosphates, those molecules can turn off the enzymes that make them.
Inositol pyrophosphates such as IP7 act as feedback inhibitors of inositol phosphate kinases. In nonvascular land plants, DELLA proteins are regulated by inositol pyrophosphate, demonstrating a conserved negative feedback loop. This feedback prevents overaccumulation of signaling intermediates.
Transcriptional repression of biosynthetic enzymes
In simple terms: Cells can reduce the amount of enzyme proteins by turning down the genes that encode them.
Expression of inositol phosphate biosynthetic enzymes such as IP6K2 and IMPAD1 is subject to transcriptional repression under specific conditions. For example, circ-IP6K2 modulates miR-1292-5p/CAMK2N1 signaling in clear cell renal cell carcinoma, indirectly affecting inositol phosphate levels.
Post-translational modification and degradation
In simple terms: Enzymes can be chemically modified or destroyed to stop them from working.
Phosphorylation of inositol phosphate enzymes by AKT and other kinases can inhibit their activity. In prostate cancer with TMPRSS2:ERG fusion, androgen deprivation enhances AKT activation, which may alter inositol phosphate metabolism. Platelet protein phosphorylation also regulates inositol phosphate formation.
Competition with phosphatases
In simple terms: Enzymes that remove phosphate groups can reverse the actions of those that add them.
Inositol monophosphatases and inositol polyphosphate phosphatases dephosphorylate inositol phosphates, effectively reducing the pool of biosynthetic products. Mutations in INPPL1 cause opsismodysplasia, highlighting the importance of phosphatase-mediated negative regulation.
Receptor-mediated inhibition
In simple terms: Signals from outside the cell can tell it to stop making inositol phosphates.
Ligation of surface IgM or IgD on murine B lymphocytes regulates inositol phosphate formation and Ca2+ mobilization, demonstrating receptor-mediated control of this pathway.
Key Genes Involved in GO:0010920 negative regulation of inositol phosphate biosynthetic process
The following genes encode enzymes, regulators, and signaling components that directly or indirectly participate in the negative regulation of inositol phosphate biosynthesis.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IP6K2 | Inositol hexakisphosphate kinase 2; produces IP7 | Circ-IP6K2 suppresses tumor progression in ccRCC |
| INPPL1 | Inositol polyphosphate phosphatase-like 1 | Mutations cause opsismodysplasia |
| IMPAD1 | Inositol monophosphatase domain containing 1 | Dephosphorylates inositol monophosphates |
| PLC | Phospholipase C; generates IP3 and DAG | Central to phosphoinositide signaling |
| IPK | Inositol polyphosphate kinase | Phosphorylates inositol phosphates |
| AKT | Serine/threonine kinase | Phosphorylates and regulates metabolic enzymes |
| CAMK2N1 | Calcium/calmodulin dependent protein kinase II inhibitor 1 | Modulated by circ-IP6K2 in ccRCC |
| DELLA | Plant growth repressor | Regulated by inositol pyrophosphate |
| miR-1292-5p | MicroRNA | Targets CAMK2N1 in ccRCC |
| TMPRSS2:ERG | Fusion oncogene | Enhances AKT activation in prostate cancer |
| IgM | B-cell receptor | Regulates inositol phosphate formation |
| IgD | B-cell receptor | Regulates inositol phosphate formation |
| Phospholipase C isoforms | Generate IP3 | Key nodes in calcium signaling |
| Inositol pyrophosphate phosphatases | Degrade IP7 | Feedback regulation |
| GPCRs | G-protein coupled receptors | Activate PLC and inositol phosphate production |
| RTKs | Receptor tyrosine kinases | Activate PLCγ and PI3K |
How Is negative regulation of inositol phosphate biosynthetic process Regulated?
Negative regulation of inositol phosphate biosynthesis is controlled by multiple mechanisms. Feedback inhibition by inositol pyrophosphates such as IP7 directly dampens kinase activity. Receptor tyrosine kinases and GPCRs can activate phospholipase C, but downstream phosphorylation by AKT may inhibit biosynthetic enzymes. In B lymphocytes, surface IgM and IgD ligation modulates inositol phosphate formation, indicating receptor-level control. Additionally, phosphatases such as INPPL1 reverse phosphorylation, providing a counterbalance.
negative regulation of inositol phosphate biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IP6K2 | Clear cell renal cell carcinoma | Knockout or overexpression in ccRCC cell lines |
| INPPL1 | Opsismodysplasia | Point mutation knock-in in osteoblast models |
| TMPRSS2:ERG | Prostate cancer | Fusion knock-in in prostate epithelial cells |
| IgM/IgD | B-cell signaling disorders | Knockout in murine B cell lines |
| PLC | Calcium signaling defects | CRISPR knockout in HEK293 cells |
Cancer
Dysregulated inositol phosphate signaling contributes to tumor progression. In clear cell renal cell carcinoma, circ-IP6K2 suppresses tumor progression by modulating the miR-1292-5p/CAMK2N1 axis, highlighting the role of negative regulation. In prostate cancer with TMPRSS2:ERG fusion, androgen deprivation enhances AKT activation, which may alter inositol phosphate metabolism.
Skeletal disorders
Mutations in INPPL1, which encodes an inositol polyphosphate phosphatase, cause opsismodysplasia, a rare skeletal dysplasia. This demonstrates that proper negative regulation of inositol phosphate levels is critical for bone development.
Immune dysfunction
In murine B lymphocytes, regulation of surface IgM- and IgD-mediated inositol phosphate formation and Ca2+ mobilization is essential for appropriate immune responses. Defects in this negative regulation can lead to aberrant B-cell activation.
From negative regulation of inositol phosphate biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IP6K2 loss alter inositol phosphate levels? | IP6K2 knockout cell line |
| Does INPPL1 mutation affect bone development? | INPPL1 point mutation knock-in mouse |
| How does TMPRSS2:ERG fusion impact AKT signaling? | Fusion knock-in prostate cancer cells |
| Does circ-IP6K2 regulate miR-1292-5p? | Overexpression of circ-IP6K2 in ccRCC cells |
| How does IgM ligation affect inositol phosphate formation? | IgM knockout B cell line |
| Does DELLA regulation require inositol pyrophosphate? | DELLA knockout plant model |
How to Study the negative regulation of inositol phosphate biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mass spectrometry | Inositol phosphate species levels | Quantifying IP3, IP4, IP5, IP6 |
| Calcium imaging | Intracellular Ca2+ flux | B-cell receptor signaling |
| CRISPR knockout | Gene function loss | IP6K2 in ccRCC |
| RNA-seq | Transcriptome changes | Identifying regulated genes |
| Proteomics | Protein expression and modifications | Phosphorylation of biosynthetic enzymes |
| Co-immunoprecipitation | Protein-protein interactions | Regulatory complex assembly |
| Luciferase reporter | Transcriptional activity | Promoter regulation of IP6K2 |
| Live-cell imaging | Subcellular localization | Enzyme recruitment to membranes |
Phosphoinositide profiling by mass spectrometry
Mass spectrometry-based lipidomics can quantify inositol phosphate species and assess the impact of negative regulators. This method is essential for measuring changes in IP3, IP4, IP5, and IP6 levels.
Live-cell calcium imaging
Calcium mobilization assays using fluorescent dyes measure downstream effects of inositol phosphate production. This is particularly useful in immune cells where receptor-mediated signaling is dynamic.
CRISPR knockout and rescue
Knocking out candidate genes such as IP6K2 or INPPL1 followed by rescue experiments can establish causality. This approach is widely used in cancer and skeletal disease models [3,5].
RNA-seq and proteomics
Transcriptomic and proteomic profiling can identify changes in expression of inositol phosphate biosynthetic enzymes and their regulators. This helps map the negative regulatory network.
How CRISPR Can Be Used to Study GO:0010920 negative regulation of inositol phosphate biosynthetic process
Knockout
CRISPR knockout of IP6K2 or INPPL1 can abolish negative regulation, leading to elevated inositol phosphate levels. This is useful for studying loss-of-function phenotypes in cancer and skeletal models [3,5].
Point Mutation
Introducing disease-associated point mutations in INPPL1 via CRISPR base editing can model opsismodysplasia and reveal how specific residues affect phosphatase activity.
Knock-in
Knock-in of the TMPRSS2:ERG fusion or tagged versions of IP6K2 allows tracking of fusion-driven signaling and protein localization in prostate cancer cells.
Overexpression
Overexpression of circ-IP6K2 or constitutively active AKT can enhance negative regulation and suppress tumor progression, providing gain-of-function models [3,1].
How EDITGENE Supports negative regulation of inositol phosphate biosynthetic process Research
Researchers studying negative regulation of inositol phosphate biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in pathway control or disease progression. EDITGENE provides validated CRISPR cell models and screening services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of inositol phosphate biosynthetic process research.
Frequently Asked Questions About negative regulation of inositol phosphate biosynthetic process
What is GO:0010920?
GO:0010920 is the Gene Ontology term for negative regulation of inositol phosphate biosynthetic process, describing any mechanism that decreases the rate of inositol phosphate production.
What genes are involved in negative regulation of inositol phosphate biosynthetic process?
Key genes include IP6K2, INPPL1, IMPAD1, PLC, and AKT, which modulate inositol phosphate levels through phosphorylation or dephosphorylation [3,5,1].
How is inositol phosphate biosynthesis negatively regulated?
It is regulated by feedback inhibition from inositol pyrophosphates, transcriptional repression, post-translational modifications, and phosphatase activity [6,3,5].
What diseases are associated with dysregulated inositol phosphate biosynthesis?
Diseases include clear cell renal cell carcinoma, opsismodysplasia, and B-cell signaling disorders [3,5,8].
What experimental models are used to study this process?
CRISPR knockout, point mutation knock-in, overexpression cell lines, and mass spectrometry-based lipidomics are commonly used [3,5,2].
How does IP6K2 regulate inositol phosphate levels?
IP6K2 produces inositol pyrophosphates that can feedback-inhibit upstream kinases, and its circular RNA form modulates miR-1292-5p/CAMK2N1 signaling [3,6].
What is the role of INPPL1 in bone development?
INPPL1 encodes a phosphatase that degrades inositol polyphosphates; mutations cause opsismodysplasia, a skeletal dysplasia.
Can CRISPR be used to study negative regulation of inositol phosphate biosynthesis?
Yes, CRISPR knockout of IP6K2 or INPPL1 and knock-in of disease mutations are powerful approaches to dissect this pathway [3,5].
What methods measure inositol phosphate levels?
Mass spectrometry, calcium imaging, and phosphoinositide profiling are standard methods [2,8].
Why is negative regulation of inositol phosphate biosynthesis important in cancer?
It prevents excessive signaling that promotes tumor progression; loss of negative regulators like circ-IP6K2 is linked to ccRCC.
Conclusion
Negative regulation of inositol phosphate biosynthetic process (GO:0010920) is a critical control point in cellular signaling, impacting cancer, bone development, and immunity. Understanding its molecular players and regulatory mechanisms offers therapeutic opportunities. EDITGENE's CRISPR services provide robust tools to investigate this pathway and identify novel drug targets.
References
- 1. Ma F et al.. 2025. Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.. J Clin Invest 135(23) PMID: 41321318
- 2. Boss WF et al.. 2012. Phosphoinositide signaling.. Annu Rev Plant Biol 63:409-29 PMID: 22404474
- 3. Tang JY et al.. 2024. Circ-IP6K2 suppresses tumor progression by modulating the miR-1292-5p/CAMK2N1 signal in clear cell renal cell carcinoma.. Funct Integr Genomics 24(4):122 PMID: 38980439
- 4. Gerrard JM et al.. 1985. Platelet protein phosphorylation.. Adv Exp Med Biol 192:235-48 PMID: 3010667
- 5. Fradet A et al.. 2017. INPPL1 gene mutations in opsismodysplasia.. J Hum Genet 62(2):135-140 PMID: 27708270
- 6. Rana P et al.. 2025. GA-independent DELLA regulation by inositol pyrophosphate in a nonvascular land plant.. Nat Chem Biol 21(11):1697-1708 PMID: 40745478
- 7. Żyła K et al.. 2025. Towards Improved Bioavailability of Cereal Inositol Phosphates, Myo-Inositol and Phenolic Acids.. Molecules 30(3) PMID: 39942756
- 8. Harnett MM et al.. 1989. Regulation of surface IgM- and IgD-mediated inositol phosphate formation and Ca2+ mobilization in murine B lymphocytes.. Eur J Immunol 19(10):1933-9 PMID: 2555196
